PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28404691-0	2017	Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.	17-hydroexemestane	37-55	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	63-101	
28404691-2	2017	The primary active metabolite of EXE, 17-hydroexemestane (17-HE), is inactivated via glucuronidation, mainly by UDP-glucuronosyltransferase 2B17 (UGT2B17).	17-hydroexemestane	38-56	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	112-144	
28404691-2	2017	The primary active metabolite of EXE, 17-hydroexemestane (17-HE), is inactivated via glucuronidation, mainly by UDP-glucuronosyltransferase 2B17 (UGT2B17).	17-hydroexemestane	38-56	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	146-153	
26608382-0	2016	Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers.	17-hydroexemestane	59-77	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	10-17	
26608382-2	2016	17-Hydroexemestane, the major and biologically active metabolite of exemestane in humans, is eliminated via glucuronidation by the polymorphic UGT2B17 phase II drug-metabolizing enzyme.	17-hydroexemestane	0-18	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	143-150	
26608382-3	2016	Previous microsomal studies have shown that UGT2B17 gene deletion affects the intrinsic hepatic clearances of 17-hydroexemestane in vitro.	17-hydroexemestane	110-128	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	44-51	
26608382-4	2016	In this open-label study we set out to assess the effect of UGT2B17 gene deletion on the pharmacokinetics of 17-hydroexemestane in healthy female volunteers with and without UGT2B17.	17-hydroexemestane	109-127	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	60-67	
26608382-7	2016	Our results showed that there were statistically significant differences in plasma 17-hydroexemestane AUC0-  (P = .0007) and urine 17-hydroexemestane C24h (P = .001) between UGT2B17 genotype groups.	17-hydroexemestane	83-101	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	174-181	
26608382-7	2016	Our results showed that there were statistically significant differences in plasma 17-hydroexemestane AUC0-  (P = .0007) and urine 17-hydroexemestane C24h (P = .001) between UGT2B17 genotype groups.	17-hydroexemestane	131-149	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	174-181	
26608382-8	2016	Our data suggest that UGT2B17 gene deletion influences 17-hydroexemestane pharmacokinetics in humans.	17-hydroexemestane	55-73	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	22-29